BioNTech (Nasdaq: BNTX) and DualityBio Receive FDA Fast Track Designation

Retrieved on: 2024-01-31 20:27:44

Tags for this article:

Biotechnology

Antineoplastic drugs

Gynaecological cancer

BioNTech

Antibody-drug conjugate

Immunology

Ovarian cancer

Pfizer-BioNTech COVID-19 vaccine

u.s. food and drug administration

Click the tags to see associated articles and topics

BioNTech (Nasdaq: BNTX) and DualityBio Receive FDA Fast Track Designation. View article details on hiswai:

Excerpt

Biopharma Stock Breaking News - BioNTech (Nasdaq: BNTX) and DualityBio Receive FDA Fast Track Designation. Next-Generation Antibody-Drug Conjugate ...

Article found on: www.investorideas.com

View Original Article